Curiteva Midline Anterior Cervical Plate System (or Curiteva Anterior Cervical Plate System)

K181549 · Curiteva, LLC · KWQ · Aug 3, 2018 · Orthopedic

Device Facts

• Record ID: K181549
• Device Name: Curiteva Midline Anterior Cervical Plate System (or Curiteva Anterior Cervical Plate System)
• Applicant: Curiteva, LLC
• Product Code: KWQ · Orthopedic
• Decision Date: Aug 3, 2018
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3060
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Curiteva Midline Anterior Cervical Plate System is intended for anterior fixation of the cervical spine (C2-T1) as an adjunct to fusion. The system is intended to provide temporary stabilization during the development of cervical spinal fusion in patients with the following: degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), spondylolisthesis, trauma (i.e., fracture or dislocation), spinal stenosis, deformity (e.g., kyphosis, scoliosis), tumors, pseudarthrosis, and/or failed previous fusion.

Device Story

Curiteva Midline Anterior Cervical Plate System consists of titanium alloy plates and screws; provides temporary stabilization of cervical spine (C2-T1) as adjunct to fusion. Implants available in various sizes to accommodate patient anatomy/pathology. Used by surgeons in clinical settings to fixate spine during fusion procedures. Device provides mechanical support to stabilize spinal segments; facilitates bone healing/fusion. Benefits include restoration of spinal stability and support for fusion in patients with degenerative, traumatic, or deformity-related conditions.

Clinical Evidence

Bench testing only. Mechanical testing performed per ASTM F1717 including static and dynamic compression bend, static torsion, and axial screw pushout. Results demonstrate performance sufficient for intended use.

Technological Characteristics

Materials: Titanium alloy (Ti-6Al-4V) per ASTM F136. Components: Plates and screws in various sizes. Non-sterile. Mechanical fixation principle. No software or electronic components.

Indications for Use

Indicated for anterior cervical spine (C2-T1) fixation as adjunct to fusion for patients with degenerative disc disease, spondylolisthesis, trauma (fracture/dislocation), spinal stenosis, deformity (kyphosis/scoliosis), tumors, pseudarthrosis, or failed previous fusion.

Regulatory Classification

Identification

A spinal intervertebral body fixation orthosis is a device intended to be implanted made of titanium. It consists of various vertebral plates that are punched into each of a series of vertebral bodies. An eye-type screw is inserted in a hole in the center of each of the plates. A braided cable is threaded through each eye-type screw. The cable is tightened with a tension device and it is fastened or crimped at each eye-type screw. The device is used to apply force to a series of vertebrae to correct “sway back,” scoliosis (lateral curvature of the spine), or other conditions.

Predicate Devices

• Zavation Cervical Plate System (K130030)
• DeGen Medical Hyper-C Anterior Cervical Plate System (K150759)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the blue square is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.

August 3. 2018

Curiteva, LLC Mr. Eric Linder Chief Operating Officer 25127 Will McComb Drive, Suite 100 Tanner, Alabama 35671

Re: K181549

Trade/Device Name: Curiteva Midline Anterior Cervical Plate System (or Curiteva Anterior Cervical Plate System) Regulation Number: 21 CFR 888.3060 Regulation Name: Spinal intervertral body fixation orthosis Regulatory Class: Class II Product Code: KWO Dated: June 11, 2018 Received: June 12, 2018

Dear Mr. Linder:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part

{1}------------------------------------------------

801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/CombinationProducts/GuidanceRegulatoryInformation/ucm597488.htm); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4. Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/) and CDRH Learn (http://www.fda.gov/Training/CDRHLearn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (http://www.fda.gov/DICE) for more information or contact DICE by email ([e-mail]) or phone [phone] or 301-796-7100).

Sincerely.

# Ronald P. Jean -S

for Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

# Indications for Use

510(k) Number (if known) K181549

#### Device Name

Curiteva Midline Anterior Cervical Plate System (or Curiteva Anterior Cervical Plate System)

#### Indications for Use (Describe)

The Curiteva Midline Anterior Cervical Plate System is intended for anterior fixation of the cervical spine (C2-T1) as an adjunct to fusion. The system is intended to provide temporary stabilization during the development of cervical spinal fusion in patients with the following: degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), spondylolisthesis, trauma (i.e., fracture or dislocation), spinal stenosis, deformity (e.g., kyphosis, scoliosis), tumors, pseudarthrosis, and/or failed previous fusion.

Type of Use (Select one or both, as applicable)

| <div> <span> <span style="text-decoration: overline;">X</span> Prescription Use (Part 21 CFR 801 Subpart D) </span> </div> |
|--------------------------------------------------------------------------------------------------------------------------------|
| <div> <span> Over-The-Counter Use (21 CFR 801 Subpart C) </span> </div> |

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff [e-mail]

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

## 510(k) Summary

#### A. Submitter Information

| Submitter: | Curiteva, LLC<br>25127 Will McComb Drive, Suite 100<br>Tanner, AL 35671<br>Phone: [phone]<br>Fax: [phone] |
|-----------------|-------------------------------------------------------------------------------------------------------------------------|
| Contact Person: | Eric Linder<br>[e-mail] |
| Date Prepared: | August 3, 2018 |

#### B. Device Information

| Trade Name: | Curiteva Midline Anterior Cervical Plate System<br>(or Curiteva Anterior Cervical Plate System) |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------|
| Common Name: | Anterior Cervical Plate System |
| Classification Name: | Appliance, Fixation, Spinal Intervertebral Body |
| Device Classification: | Class II (per 21 CFR 888.3060) |
| Product Code: | KWQ |
| Classification Panel: | Division of Orthopedic Devices |
| Predicate Device(s): | Primary: Zavation Cervical Plate System -- K130030<br>Additional: DeGen Medical Hyper-C Anterior Cervical Plate<br>System -- K150759 |

#### C. Device Description

The Curiteva Midline Anterior Cervical Plate System consists of screws and plates. These implants are available in different sizes so that adaptations can be made to take into account pathology and individual patient anatomy. All implants are manufactured from Titanium alloy (Ti-6Al-4V) that conforms to ASTM F136 and are provided non-sterile.

#### D. Indications for Use

The Curiteva Midline Anterior Cervical Plate System is intended for anterior fixation of the cervical spine (C2-T1) as an adjunct to fusion. The system is intended to provide temporary stabilization during the development of cervical spinal fusion in patients with the following:

{4}------------------------------------------------

degenerative disc disease (defined as neck pain of discogenic origin with degeneration of the disc confirmed by patient history and radiographic studies), spondylolisthesis, trauma (i.e., fracture or dislocation), spinal stenosis, deformity (e.g., kyphosis, scoliosis), tumors, pseudarthrosis, and/or failed previous fusion.

### E. Technological Characteristics

As was established in this submission, the subject Curiteva Midline Anterior Cervical Plate System is substantially equivalent to other predicate devices cleared by the FDA for commercial distribution in the United States. The subject device was shown to be substantially equivalent and to have the same technological characteristics to its predicate devices through comparison in areas including design, intended use, material composition, and range of sizes.

#### F. Performance Data

The Curiteva Midline Anterior Cervical Plate System was mechanically tested in the following test modes: static and dynamic compression bend per ASTM F1717, static torsion per ASTM F1717, and axial screw pushout.

The results of this non-clinical testing show that the strength and performance of the Curiteva Midline Anterior Cervical Plate System is sufficient for its intended use and is substantially equivalent to legally marketed predicate devices.

## G. Conclusion

Based on the indications for use, technological characteristics, performance testing, and comparison to predicate devices, the subject Curiteva Midline Anterior Cervical Plate System has been shown to be substantially equivalent to legally marketed predicate devices.